clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Hugo, the most common co-covered peer. The tracked stories average 2 original sources each. Human Tissue Authority appears in 1 tracked Biotech story from February 24, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Human Tissue Authority
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Hugo, the most common co-covered peer. The tracked stories average 2 original sources each. Human Tissue Authority appears in 1 tracked Biotech story from February 24, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Human Tissue Authority. Shared-story counts are live from our verified record — not editorial picks.
The birth of baby Hugo marks a historic milestone in British reproductive medicine as the first child born in the UK following a womb transplant from a deceased donor. This breakthrough validates the efficacy of uterine transplantation as a viable treatment for absolute uterine factor infertility (AUFI) and significantly expands the potential donor pool for the procedure.
Human Tissue Authority is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.